The study aims to compare the efficacy of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) in patients with incomplete revascularization after coronary artery bypass graft surgery (CABG). Before hospital discharge, patients will be 1:1 randomized to SAPT (acetylsalicylic acid 100 mg/die) or DAPT (acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die). DAPT will be continued for 12 months, and ticagrelor will be withdrawn thereafter. Primary endpoint is the evaluation of cardiac-related mortality at 5 years from hospital discharge.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
800
90 mg bis in die
100 mg die
Università Campus Bio-Medico di Roma
Rome, Italy
RECRUITINGCardiac-related mortality
Time frame: 5 years
Mortality
Overall mortality and non-cardiac-related mortality
Time frame: 5 years
Major adverse cardiac and cerebrovascular events (MACCEs)
cardiac-related mortality, myocardial infarction, repeated vessel revascularization, hospitalization for heart failure, major arrhythmias, stroke
Time frame: 5 years
Major adverse hemorrhagic events (MAHEs)
stroke, gastrointestinal bleeding, life-threatening bleeding
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.